| 2025-06-13 16:51 | CC:CYBN | Cybin Inc (2) | 11.20 | News Release200 | Cybin talks partnerships, regulatory signals |
| 2025-06-11 07:30 | CC:CYBN | CYBIN INC. | 12.20 | News Release200 | Cybin to Participate in the 2025 Psychedelic Science Conference |
| 2025-06-03 17:02 | CC:CYBN | Cybin Inc (2) | 11.25 | News Release200 | Cybin receives U.S. patent for CYB004 DMT program |
| 2025-05-20 12:33 | CC:CYBN | Cybin Inc (2) | 11.80 | News Release200 | Cybin hears FDA pushing for psychedelic therapeutics |
| 2025-05-15 16:49 | CC:CYBN | Cybin Inc (2) | 11.80 | News Release200 | Cybin hires Thermo Fisher for phase 3 supply of CYB003 |
| 2025-05-14 07:30 | CC:CYBN | CYBIN INC. | 11.80 | News Release200 | Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase |
| 2025-05-08 17:29 | CC:CYBN | Cybin Inc (2) | | News Release200 | Cybin receives U.S. patent for its CYB003 program |
| 2025-05-01 07:30 | CC:CYBN | CYBIN INC. | 11.80 | News Release200 | Cybin to Participate at the 28th Annual Milken Institute Global Conference |
| 2025-04-23 07:30 | CC:CYBN | CYBIN INC. | 11.80 | News Release200 | Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 |
| 2025-04-21 17:01 | CC:CYBN | Cybin Inc (2) | 11.80 | News Release200 | Cybin forms partnership with Osmind |
| 2025-02-10 21:48 | CC:CYBN | CYBIN INC. | 13.25 | News Release200 | Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights |
| 2025-02-10 20:55 | CC:CYBN | Cybin Inc (2) | 13.25 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2025-02-10 20:49 | CC:CYBN | Cybin Inc (2) | 13.25 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2025-01-15 18:18 | CC:CYBN | Cybin Inc (2) | 13.10 | News Release200 | Cybin launches partnership agreement with Segal Trials |
| 2025-01-13 20:59 | CC:CYBN | Cybin Inc (2) | 12.56 | News Release200 | Cybin summarizes 2024, looks ahead to 2025 |
| 2025-01-09 17:00 | CC:CYBN | CYBIN INC. | 13.85 | News Release200 | Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 |
| 2024-12-10 17:21 | CC:CYBN | Cybin Inc (2) | 14.45 | News Release200 | Cybin presents two posters at ACNP in Arizona |
| 2024-12-04 07:30 | CC:CYBN | CYBIN INC. | 14.85 | News Release200 | Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 |
| 2024-11-18 16:45 | CC:CYBN | Cybin Inc (2) | 14.75 | News Release200 | Cybin talks phase 2 efficacy data for CYB003 |
| 2024-11-14 07:30 | CC:CYBN | CYBIN INC. | 14.61 | News Release200 | Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 |
| 2024-11-14 07:12 | CC:CYBN | Cybin Inc (2) | 15.42 | In the News525 | Globe says Cybin, Mind Medicine score U.S. FDA nod |
| 2024-11-13 13:59 | CC:CYBN | Cybin Inc (2) | 16.00 | News Release200 | Cybin begins phase 3 program for CYB003 |
| 2024-11-13 07:34 | CC:CYBN | Cybin Inc (2) | 16.00 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2024-11-13 07:34 | CC:CYBN | Cybin Inc (2) | 16.00 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2024-10-31 07:30 | CC:CYBN | CYBIN INC. | 13.62 | News Release200 | Cybin to Participate at the 2024 Milken Institute Future of Health Summit |
| 2024-10-24 14:19 | CC:CYBN | Cybin Inc (2) | | News Release200 | Cybin receives U.S. patent for CYB005 candidates |
| 2024-10-03 07:30 | CC:CYBN | CYBIN INC. | 11.90 | News Release200 | Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024 |
| 2024-10-01 15:17 | CC:CYBN | Cybin Inc (2) | 12.00 | News Release200 | Cybin appoints Rahman, Gutierrez as VPs |
| 2024-09-24 07:30 | CC:CYBN | CYBIN INC. | 12.93 | News Release200 | Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit |
| 2024-09-19 18:00 | CC:CYBN | Cybin Inc (2) | 11.63 | News Release200 | Cybin appoints Mahableshwarkar, Macek to lead programs |
| 2024-09-19 09:24 | CC:CYBN | Cybin Inc (2) | 0.265 | News Release200 | Cybin completes 1:38 share rollback |
| 2024-09-17 18:05 | CC:CYBN | Cybin Inc | 0.27 | Rollback291 | Cybin 1:38 rollback |
| 2024-08-27 19:16 | CC:CYBN | Cybin Inc | 0.345 | News Release200 | Cybin shareholders OK matters at AGM |
| 2024-08-13 16:15 | CC:CYBN | Cybin Inc | 0.36 | News Release200 | Cybin holds FDA initial breakthrough therapy meeting |
| 2024-08-08 17:54 | CC:CYBN | Cybin Inc | 0.365 | News Release200 | Cybin has June 30 cash position of $183-million |
| 2024-08-08 07:36 | CC:CYBN | Cybin Inc | 0.365 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2024-08-08 07:36 | CC:CYBN | Cybin Inc | 0.365 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2024-08-07 07:30 | CC:CYBN | CYBIN INC. | 0.355 | News Release200 | Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference |